Idiopathic Pulmonary Fibrosis
Conditions
Keywords
Idiopathic Pulmonary Fibrosis, epigallocatechin-3-gallate, EGCG
Brief summary
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Detailed description
This is a multi-center, double-blind, placebo-controlled, dose-ranging Phase I study of once daily EGCG administered for 12 weeks. The study will assess safety, pharmacokinetics, and biomarker measurements of drug effect in IPF patients already receiving background therapy for IPF with either nintedanib or pirfenidone. Two different doses of EGCG will be studied. The rationale for this study is 1) extensive pre-clinical data in mice that EGCG is efficacious in attenuating pulmonary fibrosis by blocking collagen cross-linking and the pro-fibrotic pathway mediated by TGFβ1 signaling and 2) recently published data demonstrating that in humans EGCG is safe and capable of blocking lung tissue pro-fibrotic signaling when given two weeks prior to diagnostic surgical biopsy of pulmonary fibrosis patients, many of whom were subsequently diagnosed with IPF.
Interventions
COMBINATION_PRODUCTEGCG 300 mg + Nintedanib
Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks. Drug: Nintedanib
COMBINATION_PRODUCTEGCG 300 mg + Pirfenidone
Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks. Drug: Pirfenidone
COMBINATION_PRODUCTPlacebo 2 capsules + Nintedanib or Pirfenidone
Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks. Drug: Nintedanib Drug: Pirfenidone
COMBINATION_PRODUCTEGCG 600 mg + Nintedanib
Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks. Drug: Nintedanib
COMBINATION_PRODUCTEGCG 600 mg + Pirfenidone
Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks. Drug: Pirfenidone
COMBINATION_PRODUCTPlacebo 4 capsules + Nintedanib or Pirfenidone
Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks. Drug: Nintedanib Drug: Pirfenidone
Sponsors
Hal Chapman
University of Michigan
Cornell University
Massachusetts General Hospital
Temple University
University of Washington
University of Virginia
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All participants will be on one of the standard of care drugs (nintedanib or pirfenidone) and blindly given EGCG or placebo.
Intervention model description
There will be two stages in this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study. Participants will first be randomized to one of the four groups to receive 300 mg EGCG or placebo with one of the standard of care drugs (nintedanib or pirfenidone) for 12 weeks and 4 weeks follow-up. Once all 25 subjects at stage one have completed the study, a staged safety analysis will occur prior to opening stage two study with a higher group dose of 600 mg EGCG.
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 40-85 years old. 4. Participant has IPF satisfying the 2022 ATS diagnostic criteria, confirmed by enrolling investigator at Visit 1. 5. Participant must have been on a stable dose of nintedanib twice daily or pirfenidone three times daily dose for at least 12 weeks prior to baseline (Visit 2). 6. Participant has a FVC ≥ 50% predicted using the global lung function initiative (GLI). 7. Participant has a DLCO corrected for hemoglobin ≥ 35% predicted using the GLI. 8. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if \< 55 years or 12 months if \> 55 years, must have a negative serum pregnancy test within 1 week prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence. 9. Participant has a life expectancy of at least 9 months at Visit 1. 10. Ability to take oral medication and be willing to adhere to EGCG regimen. 11. Agreement to refrain from drinking green tea in excess of a cup a day or eating green tea extract for 4 weeks before baseline and during the trial.
Exclusion criteria
1. AST, ALT, or direct bilirubin above upper limit normal from any cause at the Screening Visit. 2. Any history of HCV or HBV infection, NASH/NAFLD, or cirrhosis. 3. Alcohol consumption greater than 7 drinks per week. 4. Participant has emphysema ≥ 50% or the extent of emphysema is greater than the extent of fibrosis as per interpretation of Site Investigator or radiologist. 5. Participant has received investigational therapy for IPF within 4 weeks before baseline (Visit 2). 6. Participant is receiving systemic corticosteroids equivalent to prednisone \> 10 mg/day or equivalent within 2 weeks of baseline visit (Visit 2). 7. Participant has any concurrent condition other than IPF that, in the Investigator's opinion, is unstable and/or would impact the likelihood of survival for the study duration or the participant's ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study. 8. Participant has baseline resting oxygen saturation of \< 89% on room air or need for continuous oxygen use at baseline visit (Visit 2). 9. Consumption of GTE products in excess of a cup of green tea a day within one month of the baseline visit (Visit 2). 10. Participant is receiving digoxin at the time of screening (Visit 1) and for the duration of the study. 11. Active respiratory infection requiring treatment with antibiotics within 4 weeks of the baseline visit (Visit 2). 12. Likely to be listed for transplant during trial participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participants with treatment-emergent adverse event (TEAE) | Up to 12 weeks | The number of participants with at least 1 treatment-emergent adverse event |
| The number of treatment-emergent adverse events (TEAE) | Up to 12 weeks | The number of treatment-emergent adverse events |
| Participants with grade 3 or 4 treatment-emergent adverse events (TEAE) | Up to 12 weeks | The number of participants with at least 1 grade 3 or 4 treatment-emergent adverse events |
| The number of grade 3 or 4 treatment-emergent adverse events (TEAE) | Up to 12 weeks | The number of grade 3 or 4 treatment-emergent adverse events |
| Participants with serious adverse event (SAE) | Up to 12 weeks | The number of participants with at least 1 serious adverse event |
| The number of serious adverse event (SAE) | Up to 12 weeks | The number of serious adverse events |
| Participants with discontinued study treatment due to adverse events (AE) | Up to 12 weeks | The number of participants who discontinued study treatment due to adverse events |
| Participants with discontinued study treatment due to serious adverse events (SAE) | Up to 12 weeks | The number of participants who discontinued study treatment due to serious adverse events |
| Participants died due to adverse events (AE) on study treatment | Up to 12 weeks | The number of participants who died due to adverse events on study treatment |
| Participants died due to adverse events (AE) within 4 weeks of discontinuation | Up to 12 weeks | The number of participants who died due to adverse events within 4 weeks of discontinuation from study treatment |
| Participants with adverse event (AE) by causality | Up to 12 weeks | The number of participants with at least 1 adverse event by causality (reasonable possibility/no reasonable possibility) |
| Adverse events (AE) by causality | Up to 12 weeks | The number of adverse events by causality (reasonable possibility/no reasonable possibility) |
| Change in individual laboratory parameters | Up to 12 weeks | Absolute and relative change in individual laboratory parameters from baseline at day 84 |
| Change in forced vital capacity (FVC) | Up to 12 weeks | Absolute and relative change in forced vital capacity from baseline at day 84 |
| Change in forced vital capacity (FVC) % predicted | Up to 12 weeks | Absolute and relative change in forced vital capacity % predicted from baseline at day 84 |
| Change in diffusing capacity for carbon monoxide (DLCO) | Up to 12 weeks | Absolute and relative change in diffusing capacity for carbon monoxide uncorrected for hemoglobin from baseline at day 84 |
| Change in total score for the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire | Up to 12 weeks | Absolute change in total score for the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire from baseline at day 84 |
| Participants with an absolute change in K-BILD of 5 points or more in either direction | Up to 12 weeks | The number of participants with an absolute change in K-BILD from baseline to day 84 of 5 points or more in either direction |
| Change in total score for the Leicester Cough Questionnaire (LCQ) | Up to 12 weeks | Absolute change in total score for the Leicester Cough Questionnaire (LCQ) from baseline at day 84 |
| Participants with an absolute change of at least 1.5 points for the LCQ | Up to 12 weeks | The number of participants with an absolute change from baseline to day 84 of 1.5 points or more in either direction for the LCQ |
| Participants with a peak level change for nintedanib or pirfenidone over 50% from screening to baseline (day 1) | Day 1 | The number of participants with a change from screening to baseline (day 1) in peak levels for nintedanib or pirfenidone of 50% or more in either direction |
| Participants with a peak level change for nintedanib or pirfenidone over 50% from baseline to day 14 | Day 14 | The number of participants with a change from baseline to day 14 in peak levels for nintedanib or pirfenidone of 50% or more in either direction |
| Participants with a trough level change for nintedanib or pirfenidone over 50% from baseline to day 14 | Day 14 | The number of participants with a change from baseline to day 14 in trough levels for nintedanib or pirfenidone of 50% or more in either direction |
| Participants with peak (cmax) levels for EGCG < 250 nM at day 14 | Day 14 | The number of participants with peak (cmax) levels for EGCG \< 250 nM at day 14 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of serum biomarker COMP at day 14 | Day 14 | Change in level of serum biomarker COMP from baseline at day 14 |
| Change of serum biomarker COMP at day 84 | Day 84 | Change in level of serum biomarker COMP from baseline at day 84 |
| Change of serum biomarker Periostin at day 14 | Day 14 | Change in level of serum biomarker Periostin from baseline at day 14 |
| Change of serum biomarker Periostin at day 84 | Day 84 | Change in level of serum biomarker Periostin from baseline at day 84 |
| Change of serum biomarker pro-MMP1 at day 14 | Day 14 | Change in level of serum biomarker pro-MMP1 from baseline at day 14 |
| Change of serum biomarker pro-MMP1 at day 84 | Day 84 | Change in level of serum biomarker pro-MMP1 from baseline at day 84 |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORHarold Chapman, MD
University of California, San Francisco
PRINCIPAL_INVESTIGATORFernando J Martinez, MD
Cornell University
PRINCIPAL_INVESTIGATORSydney Montesi
Massachusetts General Hospital
Outcome results
None listed